AbCellera plans to open Good Manufacturing Practices (GMP) manufacturing facility. The first-of- its-kind facility will be located in Canada.
The new 130,000-square-foot GMPN facility will be constructed on a current vacant two-acre site. Moreover, this expansion will increase the capabilities of bringing new antibody therapies to clinical trialsand thus supportsquickly to future pandemics.
The new construction will expand capabilities in developing new antibody therapies. Moreover, the planned building will house space for warehousing, GMP protein biologic manufacturing, laboratory and office.
The construction of the facility is scheduled for later this year. It is expected that the new facility will be ready for GMP manufacturing in early 2024.
The manufacturing facility is funded by US$125.6million grant from the Canadian government’s Strategic Innovation Fund (SIF).
The new construction will addhundrends of highly skilled scientific employees to its existing workforce of nearly 300 people in the coming years.